SCHEDULE: William Blair Trims Amicus Therapeutics Stake to 3.4%

William Blair Investment Management, LLC has reported a reduced beneficial ownership stake of 3.4% in Amicus Therapeutics, Inc. common stock.

Summary

• William Blair Investment Management, LLC filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Amicus Therapeutics, Inc.
• As of December 31, 2025, William Blair beneficially owns 10,627,717 shares of Amicus Therapeutics common stock.
• This represents 3.4% of the class of securities.
• William Blair holds sole voting power over 10,321,526 shares and sole dispositive power over 10,627,717 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal for Amicus Therapeutics, as a significant institutional investor has reduced its stake below the 5% threshold, potentially indicating a shift in investment strategy or outlook.

Negatives

• William Blair Investment Management, LLC reduced its beneficial ownership in Amicus Therapeutics, Inc. to 3.4%, indicating a partial divestment by a significant institutional investor.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional ownership changes, particularly reductions below key thresholds like 5%, can sometimes signal a shift in investor sentiment or portfolio rebalancing within the biotechnology sector, which is often sensitive to such movements.

Stakeholder Impact

• Shareholders may interpret the reduction in institutional ownership as a signal of decreased confidence or a portfolio rebalancing by William Blair Investment Management, LLC.

Key Dates

Recommendation

William Blair Investment Management, LLC's reduction of its stake in Amicus Therapeutics to 3.4% suggests a partial divestment by a notable institutional investor. While this is a negative signal, the filing itself does not provide operational or financial details to warrant a strong sell recommendation. Investors should monitor future filings and company performance for further insights, maintaining a 'hold' position in the interim.

Keywords

Amicus Therapeutics, William Blair Investment Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Healthcare